lokivetmab

anti-IL31 monoclonal antibody for the treatment of atopic dermatitis in dogs

Also Known As:

Cytopoint; ZTS-00103289

Networked: 20 relevant articles (8 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        lokivetmab: 20
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        lokivetmab: 20
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        lokivetmab: 20

Experts

1.	Walters, Rodney R: 4 articles (12/2021 - 12/2016)
2.	Mahabir, Sean P: 4 articles (10/2021 - 12/2016)
3.	Dunham, Steven A: 2 articles (12/2021 - 12/2016)
4.	Escalada, Monica: 2 articles (10/2021 - 12/2017)
5.	Moyaert, Hilde: 2 articles (10/2021 - 12/2017)
6.	Stegemann, Michael R: 2 articles (10/2021 - 12/2017)
7.	Van Brussel, Leen: 2 articles (10/2021 - 12/2017)
8.	Hoevers, Jacquelien D: 2 articles (12/2016 - 12/2016)
9.	Martinon, Olivier M: 2 articles (12/2016 - 12/2016)
10.	Michels, Gina M: 2 articles (12/2016 - 12/2016)

Related Diseases

1.	Pruritus (Itching) 12/01/2021 - "When animals were given 2.0 mg/kg lokivetmab, a significant reduction in pruritus was observed at 3-4, 4-5 and 3-5 h post-treatment (P ≤ 0.0001). " 01/07/2022 - "Once on lokivetmab, the pruritus steadily improved and was effective in resolving and maintaining remission. " 02/01/2019 - "To describe the effective treatment of pruritus associated with CM with lokivetmab in one dog. " 08/01/2019 - "This study aimed to assess changes in transepidermal water loss (TEWL) during 12 weeks of treatment with lokivetmab and its correlation with the CADESI-04 and the severity of pruritus. " 12/01/2016 - "Pruritus was reported as an adverse event during the study less frequently in the lokivetmab-treated group (4.9% and 19.3%, respectively); otherwise, adverse events occurred at a similar frequency between treatment groups. "
2.	Atopic Dermatitis (Atopic Eczema) 02/01/2022 - "Lokivetmab is an effective treatment for atopic dermatitis (AD) in dogs. " 10/01/2023 - "Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study." 08/01/2019 - "The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis." 01/23/2019 - "Proactive maintenance therapy of canine atopic dermatitis with the anti-IL-31 lokivetmab. " 06/01/2023 - "Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab."
3.	Dermatitis 08/01/2023 - "INTRODUCCIÓN: el anticuerpo monoclonal caninizado lokivetmab (LKV), dirigido contra la interleucina (IL)-31, es muy eficaz para controlar el prurito en la mayoría de los perros con dermatitis atópica (AD). " 02/01/2022 - "Lokivetmab ist eine wirksame Behandlung für die atopische Dermatitis (AD) des Hundes. " 02/01/2022 - "INTRODUCCIÓN: Lokivetmab es un tratamiento eficaz para la dermatitis atópica (AD) en perros. " 01/01/2022 - "No prospective cohort studies have been performed investigating the effects of Cytopoint in dogs with allergic dermatitis using the dosing protocol prescribed on the product label in the United States. " 01/01/2022 - "A recent retrospective study reported that Cytopoint achieved treatment success in 87.8% of the cases with allergic dermatitis. "
4.	Lymphoma (Lymphomas) 01/07/2022 - "Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma."
5.	Mast Cell Activation Disorders (Mast-Cell Disease) 02/01/2019 - "Lokivetmab treatment was effective in resolving and maintaining pruritus remission in this dog with widespread cutaneous mast cell disease. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	sulfated polyvinyl alcohol
3.	Cytokines
4.	Blood Proteins (Serum Proteins)
5.	Allergens
6.	Cyclosporine (Ciclosporin)
7.	lokivetmab
8.	Prednisone (Sone)
9.	Prednisolone (Predate)
10.	Plant Extracts

Related Therapies and Procedures

1.	Injections
2.	Therapeutics
3.	Subcutaneous Injections